There is a clear need for a molecular subtyping approach in prostate cancer to identify clinically distinct subgroups that benefit from specific therapies.
T he lineage of prostate cancer is unknown. Prostate cancer was first thought to derive from glandular luminal cells; however, there is mounting evidence that basal cells may also play a role in prostate carcinogenesis. 1 Mouse models have demonstrated that both luminal and basal cells include self-sustaining lineages that can give rise to prostate cancer. 2 Recent work has sought to characterize luminal 3 and basal 4 cells that display characteristics similar to those of stem cells. However, this is an area of active research, and the similarities and differences of luminal and basal prostate cancer remain unresolved.
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The concept of luminal-and basal-like cells and oncogenesis is not limited to prostate cancer. Luminal and basal features are thought to define key molecular subtypes in bladder cancer 7 and, most notably, in breast cancer, 8 in which the well-known PAM50 gene expression classifier identifies the major molecular subtypes of breast cancer. The PAM50 classifier categorizes breast cancer into luminal A, luminal B, HER2, and basal subtypes 8, 9 and is the basis for the commercially available Prosigna test (NanoString Technologies). 10 Furthermore, these subtypes display significant differences in prognosis and response to treatment in both breast 11 and bladder 7 cancer. Luminal and basal subtypes of bladder cancer are correlated with the luminal and basal subtypes of breast cancer, 12 suggesting that underlying biological differences that transcend the organ of origin can be identified using the PAM50 classifier.
Given that prostate and breast cancer are both hormonally driven tumors and share many oncogenic pathways, [13] [14] [15] we hypothesized that the PAM50 algorithm could identify luminal-and basal-like subtypes in prostate cancer and that these subtypes would differ in clinical outcomes and treatment response. We used gene expression data from 3782 prostate cancer samples in 7 distinct cohorts on a clinical-grade microarray platform to investigate the prognostic and predictive utility of luminal and basal subtypes in prostate cancer.
Methods

Clinical Samples and Microarray Processing
Affymetrix Human Exon 1.0 ST microarray (Affymetrix) data from formalin-fixed, paraffin-embedded radical prostatectomy samples were obtained from 6 published retrospective patient cohorts (n = 1567) and 1 prospective cohort (n = 2215), for a total of 3782 samples. Retrospective cohorts were from the Mayo Clinic, Rochester, Minnesota (2 separate cohorts) [16] [17] [18] ; Cleveland Clinic, Cleveland, Ohio 19, 20 ; Johns Hopkins University, Baltimore, Maryland 21 ; Thomas Jefferson University, Philadelphia, Pennsylvania 22 ; and Durham Veterans Affairs, Durham, North Carolina. 23 Additional cohort details can be found in the original articles. [16] [17] [18] [19] [20] [21] [22] [23] A total of 2215 deidentified, anonymized, and prospectively collected patients from clinical use of the Decipher test were obtained from Decipher GRID (clinicaltrials.gov Identifier: NCT02609269). [24] [25] [26] Clinical outcomes were not available for Decipher GRID. Microarray processing was performed in a Clinical Laboratory Improvement Amendments-certified clinical operations laboratory (GenomeDx Biosciences, Inc). Microarrays were normalized using Single Channel Array Normalization. 27 See the eAppendix in the Supplement for information regarding the androgen deprivation therapy (ADT)-matched analysis, microarray data, Gene Set Enrichment Analysis (GSEA), and statistical analyses. Data collection for the 6 retrospective cohorts was approved and supervised by the Mayo Clinic, Cleveland Clinic, Johns Hopkins University, Thomas Jefferson University, and Durham Veterans Affairs institutional review boards (IRBs).
Patient consent for the 6 retrospective cohorts was waived by the IRB of each institution. Written informed patient consent and IRB approval for Decipher GRID were obtained through Quorum Review IRB (Seattle, Washington).
PAM50 Clustering
PAM50 clustering was performed based on the original algorithm from Parker et al. 28 Source code was downloaded from the University of North Carolina Microarray Database (https: //genome.unc.edu/pubsup/breastGEO/) and used without modification. Gene expression data were median centered in each cohort individually as required by the PAM50 algorithm. The normal-like subtype was excluded because the prostate cancer samples were macrodissected, limiting the amount of normal tissue present. The HER2 subtype was also excluded given the lack of ERBB2/HER2 (OMIM: 164870) amplification in prostate cancer. 29 Assignment of subtype in the prostate cancer samples was thus assigned by greatest correlation with luminal A, luminal B, or basal.
Clinical End Points
All primary and secondary end points were preplanned. The primary clinical end point was distant metastasis-free survival (DMFS). Secondary clinical end points were biochemical recurrence-free survival (bRFS), prostate cancer-specific survival (PCSS), and overall survival (OS). All end points were defined from time of surgery until time of the event, death, or last follow-up. The primary analyses in the Decipher GRID cohort were to validate subtype gene expression patterns and associations with biological pathways and clinicopathologic markers in a contemporary cohort. Figure 1B ). The 10-year actuarial rates for bRFS are 29% for luminal B compared with 41% for luminal A and 39% for basal; for DMFS, 53% for luminal B compared with 73% for luminal A and basal subtypes; for PCSS, 78% for luminal B compared with 89% for luminal A and 86% for basal; and for OS, 69% for luminal B vs 82% for luminal A and 80% for basal.
Key Points
On univariable Cox proportional hazards analysis (Table and  eTable 2 in the Supplement) , compared with the luminal B subtype, the basal and luminal A subtypes had improved bRFS (basal: hazard ratio [HR], 0.69; 95% CI, 0.59-0.81; P < .001; luminal A: HR, 0.66; 95% CI, 0.57-0.78; P < .001), DMFS (basal: HR, 0.50; 95% CI, 0.40-0.61; P < .001; luminal A: HR, 0.42; 95% CI, 0.34-0.53; P < .001), PCSS (basal: HR, 0.59; 95% CI, 0.44-0.79; P < .001; luminal A: HR, 0.38; 95% CI, 0.27-0.53; P < .001), and OS (basal: HR, 0.69; 95% CI, 0.56-0.85; P < .001; luminal A: HR, 0.56; 95% CI, 0.45-0.70; P < .001). However, the luminal A subtype does not exhibit significantly different bRFS (HR, 1.04; 95% CI, 0.89-1.22; P = .61) or DMFS (HR, 1.17; 95% CI, 0.93-1.49; P = .18) compared with the basal subtype. Luminal A does demonstrate poorer PCSS (HR, 1.54; 95% CI, 1.09-2.16; P = .01) and OS (HR, 1.25; 95% CI, 1.00-1.55; P = .05) compared with basal, although this finding is difficult to interpret in the setting of nonsignificant differences in metastasis and biochemical recurrence. Consistent with our data demonstrating that patients with luminal B tumors have the poorest clinical outcomes, those with luminal B tumors also have the highest preoperative prostate-specific antigen (PSA) levels, Gleason score, and rates of extracapsular extension (ECE) and lymph node invasion (LNI), followed by those with basal and then luminal A tumors (eTable 1 in the Supplement). On multivariable analysis (Table and eTable We then investigated the relationship between these subtypes and luminal and basal prostate cancer lineage markers. The basal lineage CD49f signature 4 is increased in basal-like samples ( Figure 2A) . Concordantly, the luminal markers NKX3.1 (OMIM: 602041), KRT18 (OMIM: 148070), and AR (OMIM: 313700) 3 are increased in luminal-like samples ( Figure 2B -C).
Consistent with our findings for AR, the androgen activity pathway is enriched in the luminal subtypes compared with the basal subtype (GSEA normalized enrichment score, 3.93; P < .001; Figure 2C Figure 1A ), we formally examined the subtypes using the PAM50 proliferation score. 28 The luminal A subtype has a lower proliferation score than the luminal B and basal subtypes (eFigure 4 in the Supplement), which may explain the divergent clinical outcomes despite the biological similarities between the luminal A and B subtypes. We next independently validated the associations of these subtypes with biological and clinicopathologic factors in Decipher GRID, a prospectively collected cohort of 2215 expression profiles of patients who underwent prostatectomy. The PAM50 gene expression patterns are similar to those in the pooled retrospective cohorts, and trends of AR and AR-signaling (higher in the luminal subtypes), CD49f signature (higher in the basal subtype), and NKX3.1 and KRT19 (both higher in the luminal subtypes) gene expression are conserved ( Figure 3) . A total of 737 samples (33.3%) are classified as luminal A, 723 (32.6%) as luminal B, and 755 (34.1%) as basal (eTable 4 in the Supplement). We also confirmed MYC and KRAS expression patterns, which are both increased in the luminal subtypes (eFigure 3 in the Supplement). Finally, while clinical outcomes are not available for patients in the Decipher GRID cohort, the luminal B subtype demonstrates the highest Gleason scores, as well as rates of SVI, ECE, and LNI, consistent with clinical outcomes and clinicopathologic data in our retrospective cohorts (eTable 4 in the Supplement). This independent prospective validation increases our confidence that these associations are accurate and applicable in a large contemporary cohort of patients. The association between androgen signaling and luminallike prostate cancer is of particular interest given the importance of ADT in treating prostate cancer. We investigated whether these subtypes could predict response to hormonal therapy in an exploratory subgroup analysis by first designing a postprostatectomy subcohort of patients (n = 315) who were either treated with ADT (n = 105) or not treated with ADT (n = 210) matched by clinicopathologic factors (Gleason score, PSA, LNI, ECE, SVI, and positive surgical margin status), and postoperative radiotherapy ( Figure 4A and eTables 5 and 6 and the eAppendix in the Supplement). The matched cohort had a median follow-up of 13 years. In this analysis, we pooled the luminal A and basal subtypes to compare with the luminal B subtype because the luminal A and basal subtypes have similar outcomes for ADT and no ADT in the matched cohorts. In the luminal B subtype, which has the poorest prognosis of the 3 subtypes and contains patients with increased expression of AR-signaling genes, patients treated with ADT had improved DMFS compared with those who did not receive ADT (10-year metastasis rates: ADT, 33% vs no ADT, 55%; Figure 4B and C). However, in the patients with non-luminal B subtypes, patients treated with ADT had poorer DMFS compared with untreated patients (10-year metastasis rates: ADT, 37% vs no ADT, 21%; Figure 4B and C), with a similar trend in patients with the luminal A or basal subtypes. Separating patients receiving adjuvant or salvage therapy in the matched cohort results in similar trends, although the P values are insignificant owing to the reduced numbers (eFigure 5 in the Supplement). Finally, we used interaction analysis in a Cox proportional hazards model of these matched patients to demonstrate a statistically significant interaction term between ADT and the luminal B subtype. Prognostic signatures, such as Decipher 16 and the microarray version of the Cell Cycle and Progression signature, 20,32 did not predict response to postoperative ADT (eFigure 6 in the Supplement), suggesting that it is not simply more aggressive disease that responds better to postoperative ADT. The luminal B subtype represents a subgroup of prostate cancers with poor prognosis combined with biological differences in AR-signaling that result in improved response to postoperative ADT.
PAM50 clustering
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Discussion
We demonstrated in 3782 prostate cancer samples that patients with prostate cancer can be classified into luminaland basal-like subtypes by the PAM50 algorithm. The luminal A, luminal B, and basal subtypes had consistent gene expression patterns among 6 retrospective cohorts and 1 prospectively collected cohort and were correlated with clinical outcomes. Although PAM50 subtyping has been applied to other tumor types, such as lung 33 and bladder 12 cancer, to our knowledge this is the first reported use in prostate cancer and suggests that luminal and basal features are a unifying biological concept across multiple tumor types. The PAM50 gene expression patterns in prostate cancer demonstrate concordance with breast cancer. This finding is perhaps not surprising given the similarities between prostate and breast cancer. In both tumor types, gonadal steroid hormones (testosterone in prostate and estrogen and progesterone in breast) play a large role in tumor growth and progression. In addition, both tumors respond to antihormonal therapy. Moreover, circulating androgens and estrogens are present in both men and women, and the role of androgens in breast cancer and estrogens in prostate cancer is an area of active research and may indicate further commonalities between the 2 tumor types.
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Despite these similarities, we identified that, in prostate cancer, patients with luminal B disease have the poorest prognosis in contrast to the basal subtype in breast cancer. 8 While luminal subtypes are driven by the estrogen and progesterone receptors in breast cancer, luminal subtypes in prostate cancer have increased androgen receptor expression and signaling activity. Furthermore, in breast cancer, luminal subtypes are associated with response to hormonal therapy, which is unsurprising given the high correlation of luminal subtypes and estrogen receptor status.
11 Our findings again parallel this in prostate cancer, as we demonstrated that patients with luminal B tumors benefit more from ADT than do those with non-luminal B tumors. We did not find the same benefit from ADT for patients with luminal A tumors, perhaps because these patients already have a better prognosis; thus, aggressive treatment may make little difference in the eventual outcome. We also showed that patients with luminal B tumors have an elevated PAM50 proliferation score 28 luminal A tumors despite their biological similarities. Furthermore, one effect of ADT is to reduce proliferation in androgen-sensitive prostate cancers. 35 Thus, luminal B tumors may represent a high-proliferation, androgen-driven subset, which may explain why they derive the most benefit from ADT. Notably, the luminal B subtype has a proliferation score similar to the basal subtype, indicating that proliferation genes alone are not the defining drivers of poor prognosis and the association with response to ADT. Androgen deprivation therapy forms the backbone of treatment of metastatic prostate cancer 36 and has been shown to add to the effect of radiotherapy. 37, 38 However, in a systematic review, 39 adjuvant ADT in the postoperative setting has not been shown to improve overall survival, suggesting that perhaps only a subset of men have androgen-responsive tumors that are also aggressive enough to require additional postoperative therapy. In our study, we demonstrated that not only does the luminal B subtype appear to identify such a subset from retrospectively collected patients, but it also can identify these men among contemporary patients undergoing radical prostatectomy on a commercially available genomewide expression analysis that was ordered as part of their routine clinical care. 16, 17, 19, 22 Prior work in this area has focused on identifying clinical and genomic markers for response to ADT and has identified clinical factors, such as Gleason score, PSA, and metastatic disease status, as well as certain genetic polymorphisms that are associated with outcomes in men treated with ADT. 40, 41 However, Gleason score, PSA, and metastatic disease status are prognostic factors in all men, even those who do not receive ADT. Because these studies did not include a similar group of men who were not treated with ADT, it is difficult to ascertain whether these variables are predictive for response to ADT or if they are simply prognostic markers in all prostate cancers regardless of ADT treatment.
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Limitations
This study has some limitations. Owing to the retrospective nature of the cohorts, treatment selection was inevitably affected by baseline risk. Although we attempted to adjust for baseline risk with strict matching criteria, in the non-luminal B arm of the matched cohort, patients treated with ADT had poorer DMFS, indicating that the matching was not adjusted perfectly for all treatment selection confounders. Also, we grouped KIF2C  EX01  CDCA1  BIRC5  CEP55  RRM2  CCNE1  ORC6L  MYBL2  CCNB1  NAT1  CENPF  ANLN  MELK  KNTC2  CDC6  MKI67  UBE2T  MIA  PTTG1  UBE2C  MMP11  FGFR4  GRB7  CXXC5  FOXC1  PGR  ESR1  PHGDH  CDH3  ERBB2  BCL2  MAPT  BAG1  ACTR3B  EGFR  BLVRA  SFRP1  KRT5  KRT14  KRT17  TMEM45B  GPR160  MYC  MLPH  TYMS  MDM2  FOXA1 adjuvant and salvage ADT together because stratification by these variables separately in the matching process would have reduced the number of patients and statistical power even further. Therefore, these results should be considered hypothesis generating and should be independently validated, ideally in a randomized clinical trial. We are currently in the process of obtaining samples from one such trial, RTOG 96-01, 43 which will allow us to definitively test this hypothesis. Despite the fact that the PAM50 algorithm was derived in breast cancer, its classification of basal and luminal subtypes in prostate cancer samples is correlated with known prostate luminal and basal markers. We have established that the basallike subtype is associated with the basal lineage CD49f signature 4 and that the luminal-like subtype is associated with the luminal markers NKX3.1, KRT18, and AR. 3 A recent study by Zhang et al 44 described a 100-gene set representing the 50 most overexpressed genes in basal and luminal benign prostate cells. However, when sorting our samples into luminal and basal subtypes based on these 100 genes, we did not find an association with clinical outcomes in our data set (eFigure 7 in the Supplement). These differences with our findings may be due to the biological differences in benign tissue used in the study by Zhang et al 44 vs the malignant prostate cancer samples in our study. These 100 genes were also nominated based on samples from only 3 patients, which may not adequately capture the heterogeneity across prostate cancer. In contrast, the PAM50 clustering was derived specifically in malignant tissue and has been widely validated in breast cancer, bladder cancer, and now in several thousand prostate tumors. Nonetheless, the work by Zhang et al 44 further illustrates the interest in the field of exploring the biological and clinical significance of luminal and basal prostate cancer. Although the luminal A and basal subtypes are similar to each other in clinical outcomes, they are divergent with respect to basal and luminal lineage markers and androgen receptor signaling, as well as the oncogenic drivers MYC and KRAS, in which luminal A is much more similar to luminal B. The luminal A and basal subtypes also differ in proliferation scores. Our findings suggest that luminal A and basal subtypes are biologically distinct. Although these differences do not always translate into differences in prognosis (eg, ERG [OMIM: 165080] positive vs negative 45 ), they are nevertheless important in understanding disease biology and potentially for therapeutic selection. 
Conclusions
We have illustrated the clinical and genetic differences between luminal and basal subtypes in prostate cancer across nearly 4000 samples from retrospective and prospective cohorts on a commercial, high-throughput clinical platform. We believe this work not only represents a significant step forward in our understanding of prostate cancer heterogeneity but also is a potential classifier that may identify patients who benefit from postoperative ADT on a clinical-grade platform and provide guidance in personalizing patient care. 
eAppendix. Methods
Matched cohort design and predicting response to ADT
To investigate if subtype could predict ADT response, a matched cohort with 2:1 matching for ADT untreated and treated patients was created from the MCI and MCII cohorts in order to select patients from a single institution with a mix of postoperatively treated and untreated patients. This resulted in a cohort of 315 patients, 210 of which did not receive any ADT, and 105 which received ADT treatment. The decision to perform 2:1 matching was to maximize sample size using patients only from the MC cohorts. We chose to only include patients from the MC cohorts for this analysis because patients in these cohorts received a mix of adjuvant and salvage ADT and RT, allowing us to account for the effects of both in our models. JHMI patients did not receive any post-operative treatment. CCF patients did not receive adjuvant treatment, and information about salvage ADT treatment was unavailable in the dataset. All TJU and DVA patients were treated with radiation. We defined androgen deprivation therapy (ADT) as treatment (with LHRH agonist alone or in combination with androgen receptor antagonists) after radical prostatectomy but before the primary endpoint of metastasis. Matching was performed based on Gleason, prostate specific antigen (PSA, ng/mL), positive surgical margins (SM), extracapsular extension (ECE), seminal vesicle invasion (SVI), lymph node invasion (LNI), as well as post-operative radiation therapy (RT). Data on the duration and dose of ADT were not available. Supplementary Table S6 provides details of which patients in this matched cohort received adjuvant, salvage, or both ADT and/or RT. Nearly all lymph node positive patients from the MC cohorts received ADT, as well as some who received ADT for other reasons at the treating physicians' discretion.
Microarray data accession
Microarray data is available on Gene Expression Omnibus with accession numbers GSE46691, GSE62116, GSE72291, GSE62667, GSE79956, GSE79957, and GSE79915. Additional data is also freely available for academic research purposes through a material transfer agreement with GenomeDx Biosciences.
Statistical analysis
In the demographics tables, ANOVA and Chi-squared test were used to evaluate differences between continuous and categorical variables, respectively, between patient groups. Kaplan-Meier curves were generated by pooling clinical data from all available microarray cohorts. Gleason score was stratified into low (<7), intermediate (7), and high risk (8-10). PSA was stratified into low (<10 ng/mL), intermediate (10-20 ng/mL), and high risk (>20 ng/mL) in a similar manner. SM, ECE, SVI, and LNI were considered binary variables and defined by the respective institutions. Cox regression was used for both univariable and multivariable analysis (UVA/MVA). Stratification by cohort was used when performing UVA/MVA analyses to account for baseline differences between cohorts 1 . The interaction term for treatment and subtype in a Cox model was used to evaluate prediction of treatment response, and a significant interaction Wald test p-value indicated that a subtype could predict response to ADT [2] [3] [4] . Statistical significance was set as a two-tailed p-value <0.05. All statistical analyses were performed in R 3.1.2.
Gene set enrichment analysis
Functional and biological analyses of the PAM50 subtypes in prostate cancer were investigated using Gene Set (1) 124 (1) 73 (1) 315 (1) 
